Journal of psychoactive drugs最新文献_第8页

Efficacy of Screening and Brief Intervention for Alcohol Misuse in Opioid Agonist Maintenance Treatment: A Randomized Clinical Trial. 阿片类受体激动剂维持治疗中酒精滥用筛查和简短干预的疗效：随机临床试验。

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-11 DOI: 10.1080/02791072.2024.2428139

Surabhi Gupta, Renjith R Pillai, Abhishek Ghosh

{"title":"Efficacy of Screening and Brief Intervention for Alcohol Misuse in Opioid Agonist Maintenance Treatment: A Randomized Clinical Trial.","authors":"Surabhi Gupta, Renjith R Pillai, Abhishek Ghosh","doi":"10.1080/02791072.2024.2428139","DOIUrl":"https://doi.org/10.1080/02791072.2024.2428139","url":null,"abstract":"Alcohol misuse is common in persons on opioid agonist maintenance treatment (OAMT). We tested the efficacy of screening and brief intervention (SBI) for harmful/hazardous alcohol use in buprenorphine/naloxone (BNX)-assisted OAMT. It was a double-blind, parallel-group, randomized trial, where 150 participants with alcohol misuse (Alcohol Use Disorder Identification Test - AUDIT 8-19) on BNX were allocated equally to receive either a single session SBI or screening and brief advice (control). Participants were followed up at three months. The primary outcome was the change in AUDIT; other outcomes were risk transition, change in the frequency of heavy drinking, days of abstinence from alcohol, Gamma-glutamyl transferase (GGT) levels, non-prescription opioid use, and adherence to BNX. Follow-up data was gathered from 138 participants. SBI participants had a higher reduction in AUDIT scores at the follow-up (F = 129. 173, df = 1, p < .001, ηp2 =.469). A higher proportion of participants transitioned to a low-risk category in the SBI group. The SBI group showed a higher reduction in heavy drinking and days of alcohol abstinence. Although the proportion of persons with normal serum GGT increased in both groups, the difference was not significant at the follow-up. The SBI group performed better in non-prescription opioid use and BNX adherence.","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Esketamine-Induced Dissociation: A Case Report. Esketamine-Induced Dissociation：病例报告

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-10 DOI: 10.1080/02791072.2024.2424283

Jake Scarcella, Jeffrey MacDaniels, Lucinda Coffin, Thomas Schwartz

引用次数: 0

The Risk Assessment Before Dose Tapering Among Methadone Maintenance Treatment Participants: Derivation and Validation of a Nomogram. 美沙酮维持治疗参与者剂量递减前的风险评估：提名图的推导与验证。

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-10 DOI: 10.1080/02791072.2024.2424285

Chijie Wang, Qian Lu, Boyu Li, Xijia Tang, Chaonan Fan, Li Ling

{"title":"The Risk Assessment Before Dose Tapering Among Methadone Maintenance Treatment Participants: Derivation and Validation of a Nomogram.","authors":"Chijie Wang, Qian Lu, Boyu Li, Xijia Tang, Chaonan Fan, Li Ling","doi":"10.1080/02791072.2024.2424285","DOIUrl":"https://doi.org/10.1080/02791072.2024.2424285","url":null,"abstract":"Many methadone maintenance treatment (MMT) participants experienced a tapering phase. The benefit of tapering is based on a balance between meeting the desire to reduce methadone dose and reduction in relapse. We aimed to develop and validate a nomogram to assess relapse risk after dose tapering. We developed and internally validated a nomogram for risk assessment before dose tapering in 432 participants with dose tapering in the non-Guangzhou region of Guangdong, China, and externally validated it in 117 participants with dose tapering in Guangzhou. Cox regression analysis showed that the taper start week (HR = 0.14, [0.08-0.22]) was an independent risk predictor of the relapse risk after tapering. The C-index of the nomogram was 0.76 (95%CI: 0.73-0.79) in the training cohort, 0.76 (95%CI: 0.72-0.80) in the testing cohort, and 0.84 (95%CI: 0.80-0.88) in the validation cohort. Decision curve analysis showed that the nomogram had better discriminative ability than other predictors. The nomogram was developed to assess the risk of relapse for MMT participants who volunteer a tapering phase and may help participants better make decisions about whether and how to reduce the dose to minimize the harm of relapse.","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Religious Social Integration, Psychedelics, and Psychological Distress. 宗教社会融合、迷幻药和心理困扰。

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-07 DOI: 10.1080/02791072.2024.2425021

Sean M Viña

引用次数: 0

Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use. 全球迷幻药微剂量使用趋势：人口统计、药物测试行为和使用模式。

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-06 DOI: 10.1080/02791072.2024.2424284

Omer A Syed, Rotem Petranker, Emily C Fewster, Valentyn Sobolenko, Zeina Beidas, M Ishrat Husain, Stephanie Lake, Philippe Lucas

{"title":"Global Trends in Psychedelic Microdosing: Demographics, Substance Testing Behavior, and Patterns of Use.","authors":"Omer A Syed, Rotem Petranker, Emily C Fewster, Valentyn Sobolenko, Zeina Beidas, M Ishrat Husain, Stephanie Lake, Philippe Lucas","doi":"10.1080/02791072.2024.2424284","DOIUrl":"https://doi.org/10.1080/02791072.2024.2424284","url":null,"abstract":"Despite psychedelic microdosing being a growing practice, the research on the topic is still in its infancy. While several studies have described the characteristics, motivations and practices of microdosers, the differences between individuals that only microdose and those that use both micro and macrodoses of psychedelics remain unexplored. In an online survey, we collected data of 6193 psychedelic consumers of which 2488 were microdosers of up to 11 different classical and atypical psychedelics. In comparison to respondents that use both microdoses and macrodoses, exclusive microdosers were older in age (46.4 vs. 42.0 years), had a larger proportion of females (68.4% vs. 44.7%), were non-Caucasian (25.4% vs. 14.7%), urban residents (43.9% vs. 38.5%), and had a lower average lifetime use of non-psychedelic substances (3.8 vs. 4.7 substances). Most consumers (52.5%) microdosed psychedelics multiple times a month, commonly using psilocybin (74.5%), LSD (34.4%), and ketamine (15.8%), with most users (64.6%) not testing their substances. The most common reason for microdosing was improving general wellbeing (73.0%), and psychedelics were used for treating several physical and mental health conditions. Additional analyses examined spending habits of consumers. This study adds to the growing literature on the naturalistic use of psychedelic microdosers.","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aggression in a Cohort of Male Methamphetamine (METH) Users With and Without Kratom (Mitragyna speciosa Korth.) Use History in Malaysia. 马来西亚有和无 Kratom（Mitragyna speciosa Korth.）使用史的甲基苯丙胺（METH）男性使用者群体中的攻击行为。

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-06 DOI: 10.1080/02791072.2024.2424277

Yuting Yang, Christian P Müller, Darshan Singh

{"title":"Aggression in a Cohort of Male Methamphetamine (METH) Users With and Without Kratom (Mitragyna speciosa Korth.) Use History in Malaysia.","authors":"Yuting Yang, Christian P Müller, Darshan Singh","doi":"10.1080/02791072.2024.2424277","DOIUrl":"10.1080/02791072.2024.2424277","url":null,"abstract":"Methamphetamine (METH) consumption is associated with aggression. Decoction derived from the kratom (Mitragyna speciosa Korth.) leaf has been used as a METH substitute in Southeast Asia. Given its perceived benefit, we investigated the relationship between kratom use and aggression in a treatment sample of METH users with and without kratom use history. Four hundred and three male METH users participated in this cross-sectional study. A semi-structured questionnaire and several objective clinical measures were administered. Results indicate that there were no significant differences in aggression and its dimensions between METH users with and without kratom use history. However, two distinct Clusters (1 and 2) of METH users with kratom use history were studied. Users in Cluster 1 were characterized by a higher quantity and frequency of daily kratom use, longer duration of kratom use, and use of kratom at a younger age. Users in Cluster 2 exhibited the opposite characteristics. Kratom dependence and the first age of kratom use were identified as risk factors for aggression in Cluster 1. The frequency of daily kratom use appeared as a protective factor against aggression in Cluster 2. The results offer partial support to the instrumental kratom use concept; lower frequency (1 to 3 times) of kratom use may potentially minimize aggression in METH users presenting with mild to moderate kratom dependence.","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies. 掩蔽的影响：关于迷幻药研究中安慰剂控制和掩蔽的系统回顾。

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-06 DOI: 10.1080/02791072.2024.2424272

Aleksandra Barstowe, Petri J Kajonius

{"title":"Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies.","authors":"Aleksandra Barstowe, Petri J Kajonius","doi":"10.1080/02791072.2024.2424272","DOIUrl":"10.1080/02791072.2024.2424272","url":null,"abstract":"Psychedelic-assisted therapy is becoming increasingly acknowledged as an effective therapeutic intervention for various psychiatric illnesses. However, the evaluation of masking success is rarely reported in trials. The objective of the present systematic review was to evaluate placebo-control and masking in studies exploring psychedelic-assisted therapy. Nine (k = 9) studies dating between January 2010 and March 2023 were retrieved using six databases, following strict inclusion and exclusion criteria. The results show that almost 78% of the studies had, at best, \"poor\" masking success. At the same time, 60% of active placebo and 75% of inactive placebo studies showed large effect sizes. In other words, masking influences, including benign unmasking, cannot be excluded. We therefore conclude that efficacy of psilocybin, Ayahuasca, or LSD is only one of the possible interpretations of large, positive changes in symptomatology for patients suffering from, for example, alcohol use disorder, anxiety with or without life-threatening disease, anxiety and/or depression with life-threatening cancer, treatment-resistant depression or major depressive disorder. We recommend care be taken to increase successful masking procedures and discuss alternative treatment designs to better control for potential masking influences.","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Efficacy of Ashwagandha Root Extract on Cognition, Energy and Mood Problems in Adults: Prospective, Randomized, Placebo-Controlled Study. 芦根提取物对成人认知、能量和情绪问题的安全性和有效性：前瞻性、随机、安慰剂对照研究。

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-05 DOI: 10.1080/02791072.2024.2424279

Sanjiv Kale, Adrian Lopresti, Ravleen Suri, Neha Garg, Deepak Langade

{"title":"Safety and Efficacy of Ashwagandha Root Extract on Cognition, Energy and Mood Problems in Adults: Prospective, Randomized, Placebo-Controlled Study.","authors":"Sanjiv Kale, Adrian Lopresti, Ravleen Suri, Neha Garg, Deepak Langade","doi":"10.1080/02791072.2024.2424279","DOIUrl":"https://doi.org/10.1080/02791072.2024.2424279","url":null,"abstract":"This prospective, randomized, placebo-controlled study assessed the effects of Ashwagandha root extract (ARE) on cognition, energy, and mood in adults with self-reported cognitive and energy problems. Healthy subjects aged 30-75 years were randomized to receive ashwagandha (Withania somnifera) root extract (ARE) 600 mg/day (n = 60)/identical placebo (n = 60) orally for 8 weeks. Cognitive function was assessed at baseline and week 8 using a Computerized Mental Performance Assessment System (COMPASS). Secondary outcomes were Profile of Mood States Abbreviated Version (POMS-A), Mental Fatigue Scale (MFS) and Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) for effects on mood, mental fatigue and executive function, respectively, assessed at baseline, week 4 and 8. Greater improvement (p < .05) from baseline scores were seen with ARE as against placebo for COMPASS items episodic memory, working memory and accuracy of attention. ARE also improved the POMS-A, MFS and BRIEF-A scores from baseline suggesting an improvement in mood, vigor, and an increase in the executive functioning respectively with ARE. The herb was well tolerated and had a good patient compliance with no serious adverse events reported in either of the groups. This study suggests that a dose of 600 mg a day can improve cognition, energy, and mood in adults with self-reported cognitive and energy problems.","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-13"},"PeriodicalIF":2.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does the Perception of Risk Associated with Psychedelics Use Differ in Physicians According to Their Belief of Effectiveness? 医生对使用迷幻药相关风险的认识是否因其疗效信念而异？

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-04 DOI: 10.1080/02791072.2024.2424263

A Bezo, B Roméo, Y Le Strat, L Strika-Bruneau, A Benyamina, M Hermand

{"title":"Does the Perception of Risk Associated with Psychedelics Use Differ in Physicians According to Their Belief of Effectiveness?","authors":"A Bezo, B Roméo, Y Le Strat, L Strika-Bruneau, A Benyamina, M Hermand","doi":"10.1080/02791072.2024.2424263","DOIUrl":"https://doi.org/10.1080/02791072.2024.2424263","url":null,"abstract":"The aim of this study was to explore the perception of psychedelics within the medical population. Participants were asked by questionnaire about the potential of abuse, the somatic and psychiatric complications, and the risks of self-harm and aggression associated with the use of psychedelics using Likert Scales. A total of 407 participants were included. In our sample, the following means were found: 3.05 for general risk (<.001), 2.68 for self-harm risk (<.001), 2.47 for aggression (<.001), 2.71 for addictive risk (< .001), 2.76 for psychiatric disorder risk (<.001), and 2.11 for somatic disorder(< .001). Physicians from the lower mean of age were significantly more supportive of therapeutic potential, while general practitioners were significantly less likely to consider psychedelics as a treatment than specialists (<.001). By the term therapeutic potential, we meant the therapeutic value attributable to psychedelics and the risks expressed the possibility of damage caused by the use of the drug. Clinicians who considered psychedelics as a potential treatment were less likely to associate these with risks than their counterparts (<.001). The results of this study show that the perception of the danger of psychedelic use was important in the medical community in France.","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-6"},"PeriodicalIF":2.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Kratom Consumption - The Tales of Three Patients. 食用 Kratom - 三位患者的故事。

IF 2.1 4区医学

Journal of psychoactive drugs Pub Date : 2024-11-04 DOI: 10.1080/02791072.2024.2424278

Samantha A Gnanasegaram, Lauren Sexton, Corneliu N Stanciu

{"title":"Kratom Consumption - The Tales of Three Patients.","authors":"Samantha A Gnanasegaram, Lauren Sexton, Corneliu N Stanciu","doi":"10.1080/02791072.2024.2424278","DOIUrl":"https://doi.org/10.1080/02791072.2024.2424278","url":null,"abstract":"The rising prevalence of kratom use in the United States has led to increased encounters with individuals who consume kratom and those who develop Kratom Use Disorder (KUD) among healthcare professionals. This case series highlights the need for diverse treatment approaches tailored to the individual motivations for kratom consumption. Three cases are presented: one involving the progression from kratom use for energy to opioid-driven use with subsequent challenges in detoxification and transition to naltrexone necessitating buprenorphine low-dose induction for maintenance; another detailing successful inpatient detoxification using methadone and symptom-driven clonidine, followed by successful maintenance treatment with naltrexone; and a final case involving kratom consumption for pain and anxiety self-management by an individual without a history of addictive disorders, without meeting KUD criteria. These cases underscore the complexity of managing individuals who consume kratom as well as those who develop dependence, emphasizing the need for individualized treatment approaches considering various factors such as motivation for use, psychiatric comorbidities, and response to interventions.","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-4"},"PeriodicalIF":2.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0